455 reports of this reaction
1.9% of all ROMIPLOSTIM reports
#9 most reported adverse reaction
FATIGUE is the #9 most commonly reported adverse reaction for ROMIPLOSTIM, manufactured by Amgen, Inc. There are 455 FDA adverse event reports linking ROMIPLOSTIM to FATIGUE. This represents approximately 1.9% of all 24,148 adverse event reports for this drug.
Patients taking ROMIPLOSTIM who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for ROMIPLOSTIM, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for ROMIPLOSTIM:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 455 FDA reports for ROMIPLOSTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.9% of all adverse event reports for ROMIPLOSTIM, making it a notable side effect.
If you experience fatigue while taking ROMIPLOSTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.